Smoking Cessation: Medicare Decision May Give OTC Products A New Angle
This article was originally published in The Pink Sheet Daily
National coverage determination could lead to 2.8 mil. new eligible beneficiaries for treatment. OTCs and prescription nicotine replacement therapy products could get a boost as a result of the decision, assuming other private plans follow suit.
You may also be interested in...
Modification to ‘reasonable and necessary’ definition in MCIT final rule offers new avenue for drug manufacturers to get products covered in Part B. The Biden Administration will have to decide whether it will keep the Trump regulation unchanged.
The intensely negative advisory committee for Biogen’s proposed Alzheimer’s therapy was a shocker. Would it have happened if US FDA had been able to convene an in-person event instead of a ‘virtual’ one?
With landmark advisory committee meetings coming up, we take a look back at some of the memorable panel meetings over the last 20 years.